Press Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email link below.

Get News Alerts by Email

All Years	
Search	
	Go

Advanced Search

Mar 01 2022

BioLife Solutions to Attend and Present at Upcoming Investor Conferences

Cowen presentation is scheduled for Wednesday, March 9th from 12:50-1:30pm ET in Track 12

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT)...

Feb 28 2022

BioLife Solutions Reports Unaudited Fourth Quarter and Full Year 2021 Financial Results Record quarterly revenue of \$37.3 million up 153% over Q4 2020, with organic revenue growth of 64% and biopreservation media revenue growth of 64%

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies (CGT)...

Feb 21 2022

<u>BioLife Solutions to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update on February 28, 2022</u>

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

lan 10 2022

<u>BioLife Solutions Announces Preliminary 2021 Revenue of \$119 Million, Up 148% Over 2020</u>

Rionreservation Media Revenue of \$43 Million Increased 39% Over 2020

DIOPIESEI VALIOII PIEAIA NEVEIIAE OI PTJ PIIIIOII IIIEIEASEA 35/0 OVEI 2020

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced...

lan 04 2022

<u>BioLife Solutions Collaborates with Seattle Children's to Improve Viral Vector and Cell and Gene Therapy Manufacturing</u>

Sexton Cell Processing tools and CryoStor cGMP Freeze Media Incorporated in Cell and Gene Therapy Workflows

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets, today announced an...

Dec 16 2021

<u>UNICEF Selects Ultra-Low Temperature (ULT) Freezers from BioLife Solutions to Extend Thermal Stability of COVID-19 Vaccines</u>

Stirling Ultracold Freezers to be Used in Africa, the Middle East and South America

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Nov 17 2021

BioLife Solutions Ranks 353 Among Fastest-Growing Companies in North America on the 2021 Deloitte Technology Fast 500™

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced...

Nov 15 2021

BioLife Solutions Named to Inc. Magazine Inaugural List of Best-Led Companies Number 200 out of 250; more than 10,000 companies profiled

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies and the...

Nov 11 2021

BioLife Solutions Announces Third Quarter 2021 Financial Results


Total revenue up 200% over Q3 2020; organic revenue up 37% over Q3 2020 driven by 49% growth in media revenue

BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for cell and gene therapies and the...

Nov 04 2021

BioLife Solutions Announces Executive Management Changes

BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets,...



https://investors.biolifesolutions.com/press-releases?l=10&o=40